GLP-1s and the ‘Wild West’ of Wellness episode artwork

EPISODE · May 8, 2026 · 1H 13M

GLP-1s and the ‘Wild West’ of Wellness

from The Ezra Klein Show · host New York Times Opinion

Here’s a shocking number: One out of eight American adults is taking a GLP-1, like Ozempic or Zepbound, according to a KFF poll. GLP-1s are the biggest pharmaceutical story since antidepressants. But there’s still so much we don’t know. “We’re only at the beginning of what’s been called this Ozempic era,” the journalist Julia Belluz told me. “I think we’re really just at the beginning of discovering the benefits and the harms of these drugs.” These discoveries begin in the research but are also expanding into how we think about our punishing beauty standards and the blurry lines between illness and wellness. Belluz is a contributing Opinion writer and the author, with Kevin Hall, of “Food Intelligence.” She’s one of the best health and science reporters I know and has been reporting on GLP-1s for years. In this conversation, Belluz takes me through what we know — and don’t know — about GLP-1s, their unexpected uses, how they are clashing with a culture obsessed with thinness and looksmaxxing, and whether everyone should be on them. Mentioned: “The obesity pay gap is worse than previously thought” by The Economist “The Great Ozempic Experiment” by Julia Belluz Book Recommendations: Behave by Robert M. Sapolsky The Poison Squad by Deborah Blum Ultra-Processed People by Chris van Tulleken Thoughts? Guest suggestions? Email us at [email protected]. You can find transcripts (posted midday) and more episodes of “The Ezra Klein Show” at nytimes.com/ezra-klein-podcast, and you can find Ezra on Twitter @ezraklein. Book recommendations from all our guests are listed at https://www.nytimes.com/article/ezra-klein-show-book-recs. This episode of “The Ezra Klein Show” was produced by Annie Galvin. Fact-checking by Michelle Harris, with Julie Beer. Our senior engineer is Jeff Geld, with additional mixing by Johnny Simon. Our recording engineer is Aman Sahota. Our executive producer is Claire Gordon. The show’s production team also includes Marie Cascione, Rollin Hu, Kristin Lin, Emma Kehlbeck, Jack McCordick, Marina King and Jan Kobal. Original music by Pat McCusker. Audience strategy by Shannon Busta. The director of New York Times Opinion Audio is Annie-Rose Strasser. Transcript editing by Sarah Murphy and Marlaine Glicksman. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Here’s a shocking number: One out of eight American adults is taking a GLP-1, like Ozempic or Zepbound, according to a KFF poll. GLP-1s are the biggest pharmaceutical story since antidepressants. But there’s still so much we don’t know. “We’re only at the beginning of what’s been called this Ozempic era,” the journalist Julia Belluz told me. “I think we’re really just at the beginning of discovering the benefits and the harms of these drugs.” These discoveries begin in the research but are also expanding into how we think about our punishing beauty standards and the blurry lines between illness and wellness. Belluz is a contributing Opinion writer and the author, with Kevin Hall, of “Food Intelligence.” She’s one of the best health and science reporters I know and has been reporting on GLP-1s for years. In this conversation, Belluz takes me through what we know — and don’t know — about GLP-1s, their unexpected uses, how they are clashing with a culture obsessed with thinness and looksmaxxing, and whether everyone should be on them. Mentioned: “The obesity pay gap is worse than previously thought” by The Economist “The Great Ozempic Experiment” by Julia Belluz Book Recommendations: Behave by Robert M. Sapolsky The Poison Squad by Deborah Blum Ultra-Processed People by Chris van Tulleken Thoughts? Guest suggestions? Email us at [email protected]. You can find transcripts (posted midday) and more episodes of “The Ezra Klein Show” at nytimes.com/ezra-klein-podcast, and you can find Ezra on Twitter @ezraklein. Book recommendations from all our guests are listed at https://www.nytimes.com/article/ezra-klein-show-book-recs. This episode of “The Ezra Klein Show” was produced by Annie Galvin. Fact-checking by Michelle Harris, with Julie Beer. Our senior engineer is Jeff Geld, with additional mixing by Johnny Simon. Our recording engineer is Aman Sahota. Our executive producer is Claire Gordon. The show’s production team also includes Marie Cascione, Rollin Hu, Kristin Lin, Emma Kehlbeck, Jack McCordick, Marina King and Jan Kobal. Original music by Pat McCusker. Audience strategy by Shannon Busta. The director of New York Times Opinion Audio is Annie-Rose Strasser. Transcript editing by Sarah Murphy and Marlaine Glicksman.

NOW PLAYING

GLP-1s and the ‘Wild West’ of Wellness

0:00 1:13:57

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Ezra Klein Show?

This episode is 1 hour and 13 minutes long.

When was this The Ezra Klein Show episode published?

This episode was published on May 8, 2026.

What is this episode about?

Here’s a shocking number: One out of eight American adults is taking a GLP-1, like Ozempic or Zepbound, according to a KFF poll. GLP-1s are the biggest pharmaceutical story since antidepressants. But there’s still so much we don’t know. “We’re only...

Can I download this The Ezra Klein Show episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!